Reata Pharmaceuticals Inc (NASDAQ:RETA) has been assigned an average recommendation of “Buy” from the eleven research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $273.57.
Several brokerages have issued reports on RETA. LADENBURG THALM/SH SH reiterated a “positive” rating and issued a $239.00 price target (up previously from $133.00) on shares of Reata Pharmaceuticals in a report on Wednesday, October 16th. Citigroup raised their price objective on Reata Pharmaceuticals from $241.00 to $328.00 and gave the company a “buy” rating in a research note on Tuesday, November 12th. Robert W. Baird boosted their price objective on Reata Pharmaceuticals from $162.00 to $245.00 and gave the company a “positive” rating in a report on Tuesday, November 12th. Cantor Fitzgerald upped their target price on Reata Pharmaceuticals from $250.00 to $314.00 in a research report on Wednesday, November 27th. Finally, Leerink Swann set a $230.00 price target on shares of Reata Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 15th.
Shares of NASDAQ:RETA traded up $1.95 during mid-day trading on Friday, hitting $204.60. The company had a trading volume of 227,887 shares, compared to its average volume of 325,392. Reata Pharmaceuticals has a one year low of $47.50 and a one year high of $222.33. The firm has a fifty day moving average price of $195.85 and a 200 day moving average price of $113.19. The company has a market capitalization of $5.91 billion, a PE ratio of -71.29 and a beta of 2.64.
In related news, CEO James Warren Huff sold 63,000 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $86.61, for a total transaction of $5,456,430.00. Following the transaction, the chief executive officer now directly owns 164,157 shares of the company’s stock, valued at $14,217,637.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Elaine Castellanos sold 2,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $85.00, for a total transaction of $170,000.00. Following the transaction, the insider now directly owns 4,138 shares in the company, valued at $351,730. The disclosure for this sale can be found here. Over the last three months, insiders sold 103,000 shares of company stock valued at $11,049,910. Company insiders own 34.40% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Resources Investment Advisors LLC. purchased a new stake in Reata Pharmaceuticals in the 2nd quarter valued at about $25,000. Meadow Creek Investment Management LLC lifted its position in shares of Reata Pharmaceuticals by 71.4% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 336 shares of the company’s stock worth $32,000 after buying an additional 140 shares in the last quarter. Lindbrook Capital LLC purchased a new position in shares of Reata Pharmaceuticals in the 3rd quarter worth approximately $32,000. Glen Harbor Capital Management LLC grew its holdings in shares of Reata Pharmaceuticals by 71.4% in the second quarter. Glen Harbor Capital Management LLC now owns 408 shares of the company’s stock valued at $39,000 after acquiring an additional 170 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Reata Pharmaceuticals by 1,603.1% in the third quarter. Tower Research Capital LLC TRC now owns 545 shares of the company’s stock valued at $44,000 after acquiring an additional 513 shares in the last quarter. 60.04% of the stock is owned by institutional investors and hedge funds.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Featured Article: Cost of Debt
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.